Skip to main content
. Author manuscript; available in PMC: 2015 Aug 17.
Published in final edited form as: Cardiovasc Drugs Ther. 2014 Apr;28(2):115–122. doi: 10.1007/s10557-013-6502-9

Fig. 2.

Fig. 2

CAV development in cardiac allografts in Rag-1 deficient recipients. BALB/c mouse heart allografts in Rag-1−/− B6 mouse recipients were harvested on POD 100. CAV was evaluated in H&E stained paraffin sections. Data are presented as a typical image of vascular lesion in the arteries. a Heart grafts from naïve Rag-1−/− recipients—lack of Tmem cells (Group 1, n =3). b Heart grafts from Rag-1−/− recipients harboring Tmem cells (Group 2, n =8), showing severe CAV. c Heart grafts from Rag-1−/− recipients harboring Tmem cells and receiving anti-OX40L mAb treatment (Group 3, n =8)